• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. History of insulin-dependent dabetes mellitus
3. Autoimmune origin of human type 1 diabetes
4. Islet cells autoantibodies
5. Multiplicity of autoantigens in IDDM
6. An experimental model - NOD mouse
7. Natural history of type 1 diabetes
8. The transfer of diabetes
9. Insulitis transfer with purified T-cell subsets
10. Regulatory T-cells in a diabetes co-transfer model
11. Prevention of diabetes transfer by TREG
12. Objectives of immunotherapy in IDDM
13. Three features of immunotherapy of diabetes
14. Trial of CsA in recently diagnosted IDDM
15. Immunosuppression vs. immune tolerance
16. Back to NOD mouse model
17. The CD3 molecular complex
18. Diabetes remission in CD3 antibody-treated mice
19. CD3 antibody-treated NOD mice
20. Increased T-cells in anti-CD3 treated mice
21. Effect of anti-TGFbeta on remissions
22. Antibodies used in clinical trials
23. Non-mitogenic CD3 antibody treatments
24. The ChAglyCD3 antibody
25. Efficacy measurements
26. ChAglyCD3 antibody treatment: results
27. Insulin needs at 18 months
28. Proportions of circulating lymphocytes
29. EBV reactivation
30. Representative data from three patients
31. CD8 T-cell response to EBV lytic antigens
32. Conclusions
33. Acknowledgments

Topics Covered

• The history of IDDM
• Autoimmune origin of human type 1 diabetes
• Natural history and pathophysiology of type 1 diabetes
• The role of regulatory T-cells in the control of type 1 diabetes
• Objectives of immunotherapy in insulin-dependent diabetes mellitus
• The use of immunosuppressants in type 1 diabetes
• The use of tolerance promoting monoclonal antibodies in type 1 diabetes: the case of CD3 antibodies

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Cardiovascular & Metabolic
• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Reviewed on June 13, 2019
• Archived on August 31, 2020

Financial Disclosures

• Prof. Lucienne Chatenoud has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.